AnaptysBio Inc (NASDAQ:ANAB) has a beta value of 0.01 and has seen 1.39 million shares traded in the last trading session. The company, currently valued at $645.72M, closed the last trade at $21.22 per share which meant it gained $1.93 on the day or 10.01% during that session. The ANAB stock price is -94.67% off its 52-week high price of $41.31 and 42.46% above the 52-week low of $12.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.22 million shares traded. The 3-month trading volume is 920.77K shares.
The consensus among analysts is that AnaptysBio Inc (ANAB) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 6 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.7.
AnaptysBio Inc (NASDAQ:ANAB) trade information
Sporting 10.01% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ANAB stock price touched $21.22 or saw a rise of 1.16%. Year-to-date, AnaptysBio Inc shares have moved 60.27%, while the 5-day performance has seen it change 45.54%. Over the past 30 days, the shares of AnaptysBio Inc (NASDAQ:ANAB) have changed 37.17%. Short interest in the company has seen 6.03 million shares shorted with days to cover at 8.97.
Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 46.95% from current levels. The projected low price target is $19.0 while the price target rests at a high of $90.0. In that case, then, we find that the current price level is -324.13% off the targeted high while a plunge would see the stock lose 10.46% from current levels.
AnaptysBio Inc (ANAB) estimates and forecasts
The company’s shares have lost -38.76% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 225.96%.
11 analysts offering their estimates for the company have set an average revenue estimate of 7.79M for the current quarter. 9 have an estimated revenue figure of 10.02M for the next ending quarter. Year-ago sales stood 9.01M and 7.18M respectively for this quarter and the next, and analysts expect sales will shrink by -13.54% for the current quarter and 225.96% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -19.45% over the past 5 years. Earnings growth for 2025 is a modest -0.07% while over the next 5 years, the company’s earnings are expected to increase by 6.04%.
ANAB Dividends
AnaptysBio Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
Insiders own 4.44% of the company shares, while shares held by institutions stand at 116.53% with a share float percentage of 121.94%. Investors are also buoyed by the number of investors in a company, with AnaptysBio Inc having a total of 194.0 institutions that hold shares in the company. The top two institutional holders are ECOR1 CAPITAL, LLC with over 7.52 million shares worth more than $188.48 million. As of 2024-06-30, ECOR1 CAPITAL, LLC held 27.4931% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 2.87 million shares as of 2024-06-30. The firm’s total holdings are worth over $71.94 million and represent 10.4936% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Small Cap Growth Fund . As of Sep 30, 2024 , the former fund manager holds about 2.41% shares in the company for having 733.95 shares of worth $15.57 million while later fund manager owns 625.15 shares of worth $13.27 million as of Oct 31, 2024 , which makes it owner of about 2.05% of company’s outstanding stock.
